This case report describes a patient with vitreoretinal lymphoma who subacutely developed a large, peripapillary subretinal infiltrate that rapidly and spontaneously resolved.
Methods:
A case report is presented.
Results:
A 65-year-old Asian-American woman was referred for evaluation of a dense, peripapillary subretinal infiltrate in the left eye. A diagnostic vitrectomy revealed large, atypical lymphocytes with irregularly shaped nuclei, and mutational testing was positive for myeloid differentiation primary response 88 (MYD88). Prior to surgery, the patient’s subretinal infiltrate had begun to resolve spontaneously, a process that continued after surgery without initiation of systemic or local ocular therapy.
Conclusions:
Patients with vitreoretinal lymphoma may present with transient, subretinal infiltrates that can resolve without treatment.
PulidoJSJohnstonPBNowakowskiGSCastellinoARajaH. The diagnosis and treatment of primary vitreoretinal lymphoma: a review. Int J Retin Vitr. 2018;4(1):18. doi:10.1186/s40942-018-0120-4
3.
SalomãoDRPulidoJSJohnstonPBCanal-FontcubertaIFeldmanAL. Vitreoretinal presentation of secondary large B-cell lymphoma in patients with systemic lymphoma. JAMA Ophthalmol. 2013;131(9):1151–1158. doi:10.1001/jamaophthalmol.2013.334
4.
ChanCRubensteinJLCouplandSE, et al.Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist. 2011;16(11):1589–1599. doi:10.1634/theoncologist.2011-0210
5.
KimuraKUsuiYGotoH; Japanese Intraocular Lymphoma Study Group. Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma. Jpn J Ophthalmol. 2012;56(4):383–389. doi:10.1007/s10384-012-0150-7
6.
FardeauCLeeCPLMerle-BéralH, et al.Retinal fluorescein, indocyanine green angiography, and optic coherence tomography in non-Hodgkin primary intraocular lymphoma. Am J Ophthalmol. 2009;147(5):886–894, 894.e1. doi:10.1016/j.ajo.2008.12.025
7.
WhitcupSMde SmetMDRubinBI, et al.Intraocular lymphoma. Clinical and histopathologic diagnosis. Ophthalmology. 1993;100(9):1399–1406. doi:10.1016/s0161-6420(93)31469-7
8.
CassouxNMerle-BeralHLeblondV, et al.Ocular end central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm. 2000;8(4):243–250. doi:10.1076/ocii.8.4.243.6463
CouplandSEChanCCSmithJ. Pathophysiology of retinal lymphoma. Ocul Immunol Inflamm. 2009;17(4):227–237. doi:10.1080/09273940903168696
11.
CouplandSEHummelMMüllerHHSteinH. Molecular analysis of immunoglobulin genes in primary intraocular lymphoma. Investig Ophthalmol Vis Sci. 2005;46(10):3507–3514. doi:10.1167/iovs.05-0401
12.
SagooMSMehtaHSwampillaiAJ, et al.Primary intraocular lymphoma. Surv Ophthalmol. 2014;59(5):503–516. doi:10.1016/j.survophthal.2013.12.001
13.
RiemensABrombergJTouitouV, et al.Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study. JAMA Ophthalmol. 2015;133(2):191–197. doi:10.1001/jamaophthalmol.2014.4755
14.
ShahAZhouLAbrámoffMDWuX. Multiple surface segmentation using convolution neural nets: application to retinal layer segmentation in OCT images. Biomed Opt Express. 2018;9(9):4509–4526. doi:10.1364/BOE.9.004509
KaseSNambaKJinXHKubotaKCIshidaS. Spontaneous regression of intraocular lymphoma. Ophthalmology. 2012;119(5):1083–1084.e2. doi:10.1016/j.ophtha.2011.12.011
17.
TanSZSteeplesLRChhabraRJonesNP. An unusual case report of primary vitreoretinal lymphoma. BMC Ophthalmol. 2018;18(suppl 1):223. doi:10.1186/s12886-018-0860-9
18.
PakdelAMammoZHollandsHForooghianF. Regression of subretinal lymphoma after diagnostic vitrectomy. JAMA Ophthalmol. 2017;135(5):503–505. doi:10.1001/jamaophthalmol.2017.0464
19.
MatsuoTYoshinoT. Long-term follow-up results of observation or radiation for conjunctival malignant lymphoma. Ophthalmology. 2004;111(6):1233–1237. doi:10.1016/j.ophtha.2003.09.049
20.
MatsuoTIchimuraKYoshinoT. Spontaneous regression of bilateral conjunctival extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. J Clin Exp Hematop. 2007;47(2):79–81. doi:10.3960/jslrt.47.79
21.
ChangYCChangCHLiuYTTsaiKBLiuTCLinYN. Spontaneous regression of a large-cell lymphoma in the conjunctiva and orbit. Ophthal Plast Reconstr Surg. 2004;20(6):461–463. doi:10.1097/01.iop.0000144791.05993.64
22.
HorningSJRosenbergSA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med. 1984;311(23):1471–1475. doi:10.1056/NEJM198412063112303
23.
OnoKKikuchiMFunaiNMatsuzakiMShimamotoY. Natural killing activity in patients with spontaneous regression of malignant lymphoma. J Clin Immunol. 1996;16(6):334–339. doi:10.1007/BF01541669
24.
BaehringJMAndroudiSLongtineJJ, et al.Analysis of clonal immunoglobulin heavy chain rearrangements in ocular lymphoma. Cancer. 2005;104(3):591–597. doi:10.1002/cncr.21191
25.
WhiteVAGascoyneRDPatonKE. Use of the polymerase chain reaction to detect B- and T-cell gene rearrangements in vitreous specimens from patients with intraocular lymphoma. Arch Ophthalmol. 1999;117(6):761–765. doi:10.1001/archopht.117.6.761
26.
WhitcupSMStark-VanesVWittesRE, et al.Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma. Arch Ophthalmol. 1997;115(9):1157–1160. doi:10.1001/archopht.1997.01100160327010
PulidoJSRajaHVileRGSalomãoDRViswanathaDS. Mighty MyD88 in health and disease. Retina. 2016;36(3):429–431. doi:10.1097/IAE.0000000000000921
29.
RajaHSalomãoDRViswanathaDSPulidoJS. Prevalence of MYD88 L265P mutation in histologically proven, diffuse large B-cell vitreoretinal lymphoma. Retina. 2016;36(3):624–628. doi:10.1097/IAE.0000000000000996
30.
EliottD. Transvitreal chorioretinal biopsy. In: EliottDRaoPK, eds. Surgical Management of Intraocular Inflammation and Infection. JP Medical Ltd; 2013:61–68.
31.
BerenbomADavilaRMLinHSHarbourJW. Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. Eye (Lond). 2007;21(9):1198–1201. doi:10.1038/sj.eye.6702437
32.
FishbumeBCWilsonDJRosenbaumJTNeuwdtEA. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol. 1997;115(9):1152–1156. doi:10.1001/archopht.1997.01100160322009
33.
FrenkelSHendlerKSiegalTShalomEPe’erJ. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol. 2008;92(3):383–388. doi:10.1136/bjo.2007.127928
34.
SmithJRRosenbaumJTWilsonDJ, et al.Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology. 2002;109(9):1709–1716. doi:10.1016/s0161-6420(02)01125-9
35.
IttySPulidoJS. Rituximab for intraocular lymphoma. Retina. 2009;29(2):129–132. doi:10.1097/IAE.0b013e318192f574
36.
HashidaNOhguroNNishidaK. Efficacy and complications of intravitreal rituximab injection for treating primary vitreoretinal lymphoma. Transl Vis Sci Technol. 2012;1(3):1. doi:10.1167/tvst.1.3.1
37.
Abu SamraKOrayMEbrahimiadibNLeeSAnesiSFosterCS. Intraocular lymphoma: descriptive data of 26 patients including clinico-pathologic features, vitreous findings, and treatment outcomes. Ocul Immunol Inflamm. 2018;26(3):347–352. doi:10.1080/09273948.2016.1193206
38.
LarkinKLSabooUSComerGM, et al.Use of intravitreal rituximab for treatment of vitreoretinal lymphoma. Br J Ophthalmol. 2014;98(1):99–103.
39.
BatchelorTCarsonKO’NeillA, et al.Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003;21(6):1044–1049. doi:10.1200/JCO.2003.03.036
40.
PlotkinSRBetenskyRAHochbergFH, et al.Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res. 2004;10(17):5643–5646. doi:10.1158/1078-0432.CCR-04-0159
41.
AbreyLEMoskowitzCHMasonWP, et al.Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003;21(22):4151–4156. doi:10.1200/JCO.2003.05.024
42.
FeugierPVan HoofASebbanC, et al.Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23(18):4117–4126. doi:10.1200/JCO.2005.09.131
43.
ZahidUAkbarFAmaraneniA, et al.A review of autologous stem cell transplantation in lymphoma. Curr Hematol Malig Rep. 2017;12(3):217–226. doi:10.1007/s11899-017-0382-1
44.
YounesAThieblemontCMorschhauserF, et al.Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014;15(9):1019–1026. doi:10.1016/S1470-2045(14)70311-0
45.
YounesASehnLHJohnsonP,et al.PHOENIX investigators. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non–germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(15):1285–1295. doi:10.1200/JCO.18.02403
